Abeer A Alsabak¹, Ali M Janabi²

Abstract

Purpose: To investigate the hepatoprotective benefit of gemigliptin in limiting sepsis-induced hepatic injury. Methods: A total of 24 male Albino Swiss mice were randomly assigned into 4 groups (n = 6). Group 1 was control; mice underwent laparotomy without cecal ligation and puncture (CLP), group 2 underwent CLP, group 3 received dimethyl sulfoxide (DMSO) 1 h before CLP induction, and group 4 received gemigliptin (30 µg/g) intraperitoneally, 1 h before CLP. After 24 h, the mice were euthanized, and serum AST and ALT levels were determined. Also, liver tissues were assessed for biomarkers like NF-kB, MDA, caspase-3, and p-mTOR. Histological examination of hepatic tissues was conducted using hematoxylin and eosin (H & E) stain. Results: ALT, AST, NF-kB, MDA, caspase-3, and hepatic damage scores were significantly higher compared to control following CLP induction. Furthermore, treatment with gemigliptin significantly lowered serum ALT, AST, NF-kB, MDA, caspase-3 and hepatic damage scores. Also, gemigliptin significantly decreased p-mTOR levels compared to groups 2 and 3. Conclusion: Gemigliptin significantly reduces serum ALT, AST, NF-kB, MDA, caspase-3, hepatic damage scores, and p-mTOR levels when compared with group 2 or group 3.